|
|
|
市場調查報告書
肺癌疫苗和治療用抗體：生產線、策略、臨床
Lung Cancer Vaccines and Therapeutic Antibodies: Pipeline, Strategies and Clinical
|
肺癌疫苗和治療用抗體：生產線、策略、臨床 是由出版商BioPharm Reports (Technology and Markets Ltd)在2011年10月所出版的。
這份英文市場調查報告書包含186 Pages 價格從美金2384起跳。
肺癌為全球最普遍的癌症、2008年有160萬件的新病例、140萬人死亡（因癌症的全數死亡數約20%）。5年生存率較其他癌症低（15∼20％）。在美國、肺癌治療費（2006年）為所有癌症中最高之病症。
本報告書內容包括:肺癌的免疫療法之總體展望、治療用疫苗和抗體為焦點、主要適應之研究開發和臨床開發趨勢的彙整、內容綱要摘記如下:
實施摘要
第1章 背景
- 肺癌
- 統計
- 診斷
- 肺癌的病期
- 肺癌治療
- 生存率
- 肺癌成本
- 新的開發
- 本報告書
第2章 已認定及後期階段的治療用抗體
第3章 已認定及後期階段的疫苗
- 介紹
- 概要
- 已認定疫苗
- 第3階段疫苗
- 第2/3階段疫苗
- 參考
第4章 早期段階治療用抗體
- 介紹
- 概要
- 第2層抗體
- 第1/2階段抗體
- 第1階段抗體
- 前臨床階段抗體
- 參考
第5章 早期階段疫苗
- 介紹
- 概要
- 第2階段疫苗
- 第1/2階段疫苗
- 第1階段疫苗
- 前臨床階段疫苗
- 參考
第6章 其他候補治療藥
- 介紹
- 概要
- 免疫活性劑：第2階段
- 抗體共役：第1/2階段
- 二重特異性抗體：第1階段
- 抗體共役：第1階段
- 免疫刺激劑：第1階段
- 抗體共役：第1階段
- 參考
第7章 考察
- 背景
- 生產線
- 治療用抗體
- 疫苗
- 其他候補治療藥
- 企業
- 治療標的
- 治療對策
- 症狀
- 市場的展望
- 參考
圖表
Abstract
This report provides a comprehensive review of 27 candidate therapeutic
antibodies and 42 candidate vaccines that are being evaluated for the
treatment of lung cancer, covering pipeline, disease-targeting strategies and
clinical findings. These antibodies are directed at 17 targets, while the
vaccines are directed at 24 antigens or antigen combinations.
Globally, lung cancer is the most common cancer and in 2008 there were an
estimated 1.6 million new cases and 1.4 million deaths (almost 20% of all
cancer deaths) caused by this disease. Five-year survival rates are also low
(15-20%) compared to other common cancers. In the US, studies have shown that
lung cancer-care costs (in 2006) were the third highest of all cancers, while
indirect costs (2005) were higher than for any other cancer.
Patient needs and the high burden of lung cancer are driving the development
of new therapies. While improvements have been seen in diagnosis and
treatments (surgery, radiotherapy, chemotherapy and targeted drugs), new
therapies that build on the capabilities of existing strategies, are urgently
required. Today, advances continue to be made in drug treatments for lung
cancer; in chemotherapy, new drug combinations and targeted molecules. In
particular, advances are being seen in the field of immunotherapy, in the
development of new therapeutic antibodies and therapeutic vaccines.
This Report
This report provides a comprehensive review of lung cancer immunotherapy. With
a focus on therapeutic vaccines and antibodies, it reviews R&D and clinical
developments in the treatment of lung cancer as the primary indication, as
well as studies that are evaluating lung cancer alongside other cancers. It
provides a comprehensive review of pipeline developments, therapeutic
strategies and clinical findings, covering therapeutic vaccines and antibodies.
Today, around 70 immunotherapies are being developed or evaluated for the
treatment of lung cancer. This report reviews developments on 27 candidate
therapeutic antibodies and 42 candidate vaccines for treating lung cancer,
most of which are in clinical development.
The lung cancer immunotherapy pipeline is showing substantial innovation and
many new strategies are being evaluated. Today' s pipeline of therapeutic
antibodies are directed at 17 drug targets. On the vaccine front, 24 different
antigen/multiple antigen targeting strategies are being investigated. For the
purpose of this report, multiple antigen targeting vaccines have been treated
as single targeting strategies.
More than 90% of the immunotherapy candidates in development or being
evaluated for treating lung cancer that are identified in this report, are in
clinical development. This report gives an overview of the status and clinical
findings of these candidate therapies. It also gives developmental and
market-related perspectives in this rapidly developing field.
Key content:
- Late-stage (Phases 2/3, 3 and Approved, n = 4) therapeutic antibodies and
companies
- Early-stage (Preclinical and Phases 1, 1/2 and 2, n= 23) therapeutic
antibodies and companies
- Late-stage (Phases 2/3, 3 and Approved, n = 5) vaccines and companies
- Early-stage (Preclinical and Phases 1, 1/2 and 2, n= 37) vaccines and
companies
- Other (mainly antibody related, n=6) candidate therapies in the
development pipeline for targeting lung cancer, Phases 1, 1/2 and 2
- Drug targets against which therapeutic antibodies are being directed, from
preclinical through to Phase 3, and Approved
- Antigen/antigen combinations being targeted by vaccines, from preclinical
through to Phase 3, and Approved
- Descriptions of clinical trials (patients and numbers, conditions,
treatments, regimens, Phases 1-3) of therapeutic antibodies and vaccines being
evaluated for the treatment of lung cancer
- Summaries of the clinical status and clinical findings (safety, adverse
events and multiple event-related clinical responses), following clinical
trials (Phases 1-3) of therapeutic antibodies being evaluated for the
treatment of lung cancer
- Summaries of the clinical status and clinical findings (safety, adverse
events and multiple event-related clinical responses), following clinical
trials (Phases 1-3) of vaccines being evaluated for the treatment of lung
cancer
- Commercial partnerships and collaborations on pipeline therapeutic
antibodies and vaccines
- Drug combination strategies in the evaluation of therapeutic antibodies
and vaccines for targeting of lung cancer
- A comprehensive listing of salient details of clinical trials of
therapeutic antibodies and vaccines being evaluated for the treatment of lung
cancer
- Technical and market insights and perspectives in the development and
clinical evaluation of therapeutic antibodies and vaccines for the treatment
of lung cancer
- Competitive and market-related information
Table of Contents
Executive Summary
Chapter 1 - Background
- 1. Lung Cancer
- 1.1. Statistics
- 1.2. Diagnosis
- 1.3. Lung Cancer Staging
- 1.4. Treatment of Lung Cancer
- 1.5. Survival Rates
- 1.6. Cost of Lung Cancer
- 1.7. New Developments
- 1.8. This Report
Chapter 2 - Approved and Late-Stage Therapeutic Antibodies
- Summary
- 2.1. Introduction
- 2.2. Overview
- 2.3. (One antibody, Approved)
- 2.4. - 2.6 (Three antibodies, Phase 3)
Chapter 3 - Approved and Late-Stage Vaccines
- Summary
- 3.1. Introduction
- 3.2. Overview
- 3.3. (One vaccine, Approved)
- 3.4. - 3.6 (Three vaccines, Phase 3)
- 3.7. (One vaccine, Phase 2/3)
Chapter 4 - Early-Stage Therapeutic Antibodies
- Summary
- 4.1. Introduction
- 4.2. Overview
- 4.3. - 4.12. (Ten antibodies, Phase 2)
- 4.13. - 4.18. (Six antibodies, Phase 1/2)
- 4.19. - 4.23. (Five antibodies, Phase 1)
- 4.24. - 4.25. (Two Antibodies, Preclinical)
Chapter 5 - Early-Stage Vaccines
- Summary
- 5.1. Introduction
- 5.2. Overview
- 5.3. - 5.12. (Ten vaccines, Phase 2)
- 5.13. - 5.22. (Ten vaccines, Phase 1/2)
- 5.23. - 5.37. (Fifteen vaccines, Phase 1)
- 5.38. - 5.39. (Two vaccines, Preclinical)
Chapter 6 - Other Candidate Therapies
- Summary
- 6.1. Introduction
- 6.2. Overview
- 6.3. (One Immune Activator, Phase 2)
- 6.4. (One Antibody Conjugate, Phase 1/2)
- 6.5. (One Bispecific Antibody, Phase 1)
- 6.6. (One Antibody Conjugate, Phase 1)
- 6.7. (One Immune Stimulant, Phase 1)
- 6.8. (One Antibody Conjugate, Phase 1)
Chapter 7 - Discussion
- 7.1. Background
- 7.2. Pipeline
- 7.3. Therapeutic Antibodies
- 7.4. Vaccines
- 7.5. Other Candidate Therapies
- 7.6. Companies
- 7.7. Therapeutic Targets
- 7.8. Therapeutic Approaches
- 7.9. Conditions
- 7.10. Market Perspectives
Tables
- 1.1. Global incidence and mortality from lung cancer, 2008
- 1.2. NSCLC survival rates, according to cancer stage
- 1.3a. Five-year relative cancer survival rates in the USA, for white males
- 1.3b. Five-year relative cancer survival rates in the USA for white females
- 1.4. US national expenditure on different cancers (2006).
- 1.5. US lost productivity due to different cancer types in the US, 2005
- 2.1. Approved/late-stage candidate therapeutic antibodies for the
treatment of lung cancer
- 3.1. Approved/late-stage vaccines for the treatment of lung cancer
- 4.1. Early-stage therapeutic antibodies being developed or evaluated for
the treatment of lung cancer or for lung cancer/other cancers
- 5.1. Early-stage vaccines being developed or evaluated for the treatment
of lung cancer or lung cancer/other cancers
- 6.1. Other (largely antibody-related) therapies being developed or
evaluated for the treatment of lung cancer or lung cancer/other cancers
- 7.1. Approved/late-stage therapeutic antibodies being developed for the
treatment of lung cancer
- 7.2. Early-stage candidate therapeutic antibodies being developed or
evaluated for the treatment of lung cancer or for lung cancer/other cancers
- 7.3. Approved/late-stage candidate vaccines being developed for the
treatment of lung cancer
- 7.4. Early-stage candidate vaccines being developed or evaluated for lung
cancer or for lung/other cancers
- Other (primarily antibody-related) therapies in development or being
evaluated for lung cancer or for lung cancer/other cancers
- Approved/candidate therapeutic antibodies for the treatment of lung cancer
or for lung cancer/other cancers
- Approved/candidate vaccines for the treatment of lung cancer or for lung
cancer/other cancers
- Other candidate therapies (primarily antibody-related) for the treatment
of lung cancer or for lung cancer/other cancers.
- NSCLC survival rates, according to cancer stage
Figures
- 4.1. Early-staged pipeline therapeutic antibodies for the treatment of
lung cancer or lung cancer/other cancers
- 5.1. Early-staged pipeline vaccines for the treatment of lung cancer or
lung cancer/other cancers
- 7.1. Approved and pipeline therapeutic antibodies, vaccines and other
(primarily antibody-based) therapies being developed or evaluated for the
treatment of lung cancer or for lung cancer/other cancers
- 7.2. Approved and pipeline therapeutic antibodies and vaccines being
developed or evaluated for the treatment of lung cancer or for lung
cancer/other cancers
- 7.3. Late and early-stage therapeutic antibodies, vaccines and other
(primarily antibody-based) therapies being developed or evaluated for the
treatment of lung cancer or for lung cancer/other cancers
- 7.4. Approved and pipeline therapeutic antibodies being developed or
evaluated for the treatment of lung cancer or for lung/other cancers
- 7.5. Early-stage pipeline vaccines in development or being evaluated for
lung cancer or for lung/other cancers
- 7.6. Other (primarily antibody-related) early-stage candidate therapies in
development or being evaluated for lung cancer or for lung cancer/other cancers
- 7.7. Organisations engaged in the development or evaluation of therapeutic
antibodies, therapeutic vaccines and other therapies for lung cancer or lung
cancer/other cancers
- 7.8. Countries of organisations engaged in the development/evaluation of
therapeutic antibodies, therapeutic vaccines and other therapies for lung
cancer or lung cancer/other cancers
- 7.9. Geographic regions of organisations engaged in the development or
evaluation of therapeutic antibodies, therapeutic vaccines and other therapies
for lung cancer or lung cancer/other cancers
- 7.10. Organisations developing or evaluating lung cancer therapeutic
antibodies
- 7.11. Organisations developing or evaluating lung cancer therapeutic
vaccines
- 7.12. Clinical trials of therapeutic antibodies for the treatment of lung
cancer or lung cancer/other cancers, involving single or combination agents.
- 7.13. Clinical trials of vaccines for the treatment of lung cancer or lung
cancer/other cancers, involving single or combination agents
|
 |
